- Home
- HL vs KRYS Comparison
HL vs KRYS Comparison
Compare HL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- KRYS
- Stock Information
- Founded
- HL 1891
- KRYS 2015
- Country
- HL United States
- KRYS United States
- Employees
- HL N/A
- KRYS N/A
- Industry
- HL Precious Metals
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HL Basic Materials
- KRYS Health Care
- Exchange
- HL Nasdaq
- KRYS Nasdaq
- Market Cap
- HL 4.1B
- KRYS 3.6B
- IPO Year
- HL N/A
- KRYS 2017
- Fundamental
- Price
- HL $5.55
- KRYS $125.00
- Analyst Decision
- HL Buy
- KRYS Strong Buy
- Analyst Count
- HL 5
- KRYS 8
- Target Price
- HL $7.20
- KRYS $211.13
- AVG Volume (30 Days)
- HL 20.8M
- KRYS 436.2K
- Earning Date
- HL 05-01-2025
- KRYS 05-06-2025
- Dividend Yield
- HL 0.29%
- KRYS N/A
- EPS Growth
- HL N/A
- KRYS 109.01
- EPS
- HL 0.11
- KRYS 4.16
- Revenue
- HL $1,001,736,000.00
- KRYS $333,448,000.00
- Revenue This Year
- HL $12.70
- KRYS $48.66
- Revenue Next Year
- HL $0.57
- KRYS $49.81
- P/E Ratio
- HL $45.96
- KRYS $30.31
- Revenue Growth
- HL 41.04
- KRYS 247.53
- 52 Week Low
- HL $4.41
- KRYS $122.80
- 52 Week High
- HL $7.68
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- HL 59.70
- KRYS 33.43
- Support Level
- HL $5.03
- KRYS $123.03
- Resistance Level
- HL $5.38
- KRYS $127.59
- Average True Range (ATR)
- HL 0.20
- KRYS 4.22
- MACD
- HL 0.07
- KRYS 0.73
- Stochastic Oscillator
- HL 92.52
- KRYS 26.08
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Nevada Operations. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada , United States and Mexico and it derives a majority of its revenue from United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.